Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide has a half-life of roughly seven days, which means it takes about five weeks for a single dose to clear your system almost entirely. That long-acting profile is precisely why Wegovy is injected just once a week: blood levels stay high enough throughout the week to maintain appetite suppression and slow gastric emptying. Because these are prescription-only medicines, a clinician reviews whether they are appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people inject on a Monday evening, pop the used pen in a sharps container, and then wait. A fair question follows: is it doing anything yet? Semaglutide binds to albumin in the bloodstream, and that binding is what gives it the unusually long half-life of around seven days. After a single 0.25 mg starter dose, the medicine reaches its peak concentration roughly one to three days later, then declines slowly. You probably won't feel a dramatic shift from dose one; the starter dose is designed to let your digestive system adjust rather than deliver full therapeutic effect. Real changes in appetite often become more noticeable after several weeks of consistent dosing, once blood levels have built to a steady state across the weekly cycle. If you're curious about the timeline from first injection to meaningful weight change, the Wegovy timeline page covers that in detail. The point here is that semaglutide is never a quick-in, quick-out drug, and if you want to understand exactly how long semaglutide stays in the body at each stage, its chemistry is built for persistence.
With a seven-day half-life, each dose is still roughly 50 percent present in your body when the next injection is due. That overlap is intentional. After about four to five consecutive weekly doses, semaglutide reaches what pharmacologists call steady state: the amount entering your system each week roughly equals the amount being cleared. At steady state, the appetite-suppressing and gastric-emptying effects are at their most consistent. This is one reason clinical trials measure outcomes at 68 or 72 weeks rather than a few months. The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks at the 2.4 mg dose and reported an average body-weight reduction of around 15 percent. That result reflects sustained, elevated drug levels, not a single-dose effect. Practically, steady state also means that missing one dose doesn't immediately undo the medicine's action, but deliberately stopping does start a predictable countdown. If you've noticed your progress slowing after several months, the reasons are usually more complex than drug levels alone; there's a useful breakdown on the Wegovy plateau page.
This is probably the question you actually came here to answer. If you stop semaglutide injections, the half-life logic runs in reverse: roughly half the remaining concentration clears every seven days. After five half-lives (around five weeks), circulating semaglutide has fallen to less than about three percent of the level present at your last dose. In practice, most of the pharmacological effect has gone by four to six weeks after the final injection. The NHS patient information for semaglutide notes that after stopping, patients should not try to conceive until two months have passed, reflecting this clearance window. For the broader question of how long semaglutide's effects persist in your system after stopping, the dedicated page on that question goes further. Appetite tends to return gradually as levels fall, which is why abrupt stopping without a plan is something prescribers think about carefully. If you're weighing how long you'd stay on treatment altogether, that's a separate clinical question covered on this page about long-term semaglutide use.
The molecule itself doesn't change depending on the delivery format. Whether semaglutide is injected as a 2.4 mg weekly Wegovy dose, taken as the newer 25 mg daily Wegovy tablet, or given at the higher 7.2 mg dose (the single-dose pen approved by the MHRA in April 2026), the half-life of the semaglutide molecule remains approximately seven days. The oral tablet is absorbed differently because it's co-formulated with an absorption enhancer to survive the gut, but once in circulation it behaves the same way. One practical difference: the daily tablet produces a smoother daily peak-and-trough pattern rather than the weekly cycle of an injection, though the underlying pharmacokinetics are comparable. If you're considering your options or thinking about cost alongside clinical factors, the Wegovy price comparison page is worth reading before your consultation. At nume, a real clinician reviews every consultation on the same day it's submitted. Semaglutide is a prescription-only medicine, and the prescriber decides which formulation and dose fits your situation. If you're ready to have that conversation, you can start your free consultation today.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.